WO2002096221A2 - Skin diet - Google Patents
Skin diet Download PDFInfo
- Publication number
- WO2002096221A2 WO2002096221A2 PCT/GB2002/002538 GB0202538W WO02096221A2 WO 2002096221 A2 WO2002096221 A2 WO 2002096221A2 GB 0202538 W GB0202538 W GB 0202538W WO 02096221 A2 WO02096221 A2 WO 02096221A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- foodstuff
- skin
- vitamin
- aloe vera
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/122—Coated, filled, multilayered or hollow ready-to-eat cereals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/135—Individual or non-extruded flakes, granules or shapes having similar size, e.g. breakfast cereals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present invention provides a foodstuff comprising vitamin C, taurine, curcumin and aloe vera, its use in the control of skin disorders and methods for controlling skin disorders.
- a healthy skin and coat indicates an animal in general good health.
- Skin disorders such as flea allergy or atopy cause discomfort or distress to an animal.
- such disorders reduce the actual or perceived condition of the skin or hair of an animal. It is therefore an aim of this invention to provide a foodstuff, which can be used to assist in the treatment of skin disorders in an animal, particularly in a dog.
- the provision of a foodstuff to control skin disorders is convenient for the owner as the foodstuff can be administered instead of or in combination with the animal's conventional food.
- administration of the foodstuff avoids the inconvenience and distress associated with the use of shampoos or skin ointments, creams or lotions.
- the foodstuff of the invention utilises ingredients which can occur naturally to provide a benefit to an animal. This will overcome any real or perceived disadvantage in treating an animal with drugs, primarily prescription drugs.
- the first aspect of the invention provides a foodstuff comprising vitamin C, taurine, curcumin and aloe vera.
- Aloe vera is obtained from Aloe sp. plants, which are members of the lily (Liliaceae) family.
- aloe vera can be obtained from any member of this family, including from one or more of Aloe barbadensis, Aloe arborescens, Aloe plicatuis, Aloe rahombe, Aloeferrox, Aloe perryi, Aloe chinensis, Aloe elongata, Aloe indica, Aloe officinalis, Aloe perfoliata, Aloe rubescens, Aloe vera L.var Uttoralis, Aloe vulgaris or Aloe saponaria.
- Aloe vera can be obtained from any part of the Aloe plant including the skin, leaf, stem, shoot, bulb, root, fruit, flower or seed.
- Aloe vera is obtained from the leaf.
- aloe vera can be provided as whole leaf, a gel (for example a mucilage), a exudate (yellow latex), a juice, a concentrated extract, and/or a freeze dried powder.
- aloe vera can be provided dried, fresh, crushed, in solution, in oil, as a powder, liquid, (either as a solution or as an oil or juice) or semi solid.
- the aloe vera is provided as a freeze dried powder. More preferably the freeze dried powder is substantially free of aloin and aloe-emodin.
- the aloe vera of the first aspect is preferably provided from the outer leaf of the Aloe sp. plant.
- the plant material is treated with one or more enzymes to remove fibrous backbone and/or solid debris.
- Aloin and aloe-emodin is preferably removed from the plant material for example by passing the plant material over charcoal.
- the plant material provides less than 20ppm aloin and less than lOppm aloe-emodin, more preferably less than 15ppm aloin and 5ppm aloe-emodin.
- the powder is then freeze dried. Such a powder comprising 100% active agents is designated a 100% active solid.
- the aloe vera is preferably provided as a 100% active solid or the equivalent thereof.
- Aloe vera contains a number of different components, including those summarised below.
- the aloe vera may provide one or more of the above-listed components.
- the aloe vera provided may contain further components in addition to those listed above, for example phenols, tannic acid etc.
- aloe vera may provide one or more of the following therapeutic benefits; improvement of collagen repair, prevention of hair loss, anti-inflammatory, anti-irritant, antiseptic, anti-oxidant, reduction of flea irritation, anti-microbial, reduced secondary skin infections and improved recovery from skin disorders.
- Aloe vera is provided in the foodstuff of the first aspect at a level (all per 400 kcal) of between approximately lmg and approximately lOOOmg, preferably between approximately lOmg and approximately 500mg, more preferably between approximately 20mg and approximately 150mg, more preferably approximately 40mg to approximately 90mg.
- aloe vera is provided at a level of 70 mg or above per 400kcal. The above levels are provided where Aloe vera is a 100% active solid. Where the aloe vera is provided in an alternative form, an equivalent amount of aloe vera can be provided (for example, for a 50% active solid, approximately twice as much aloe vera will be provided in the foodstuff of the first aspect).
- the foodstuff of the first aspect comprises vitamin C.
- Vitamin C is a water- soluble substance which has a number of important roles in the body. It has an essential role in the maintenance of healthy teeth, gums and bones. It aids the healing of wounds, scar tissue and fractures and strengthens blood vessels. Vitamin C also builds resistance to infection and aids in the prevention and treatment of the common cold. Vitamin C is also one of the major antioxidant nutrients.
- the vitamin C according to the first aspect of the invention may be in any form. It may be liquid, semi-solid or solid. Vitamin C for the purposes of this invention is provided at a level (all per 400 kcal) of approximately 20mg to approximately 500mg, preferably approximately 150 mg to approximately 400mg, more preferably at a level of approximately 350mg or above.
- the foodstuff of the first aspect further comprises curcumin.
- Curcumin is a major component of tumeric (Curcuma longa). Curcumin has a number of beneficial activities including inhibition . of tumour initiation, anti- inflammatory, anti-oxidant, suppression of mitogen-induced proliferation of blood mono-nuclear cells, inhibition of mixed lymphocyte reaction and inhibition proliferation of smooth muscle cells.
- curcumin has immunoglobulin production-regulating activity and has been shown to induce reductions in immunoglobulin E and M and increases in immunoglobulin G.
- the immunoglobulin regulating activity is useful for treating the inflammation associated with secondary infection, atopy and flea allergy. By reducing the inflammation, the pain associated with this reaction can also be reduced. As a secondary use, by reducing the inflammation, the complex processes involved in recovery can proceed unhindered and with appropriate speed.
- Curcumin is provided at a level (all per 400 kcal) of approximately lOOmg to approximately lOOOmg, preferably approximately 200mg to approximately 800mg, more preferably at a level of approximately 500mg or above.
- the foodstuff of the first aspect comprises taurine.
- Taurine is a non-essential amino acid which is obtained from meat and fish. It stimulates the production of glycosphingolipids in the skin by acting as a precursor molecule. Glycosphinogolipids exhibit anti-microbial properties.
- Taurine is provided in the foodstuff at a level (all per 400 kcal) of from approximately lOOmg to approximately lOOOmg, preferably from approximately 150mg to approximately 800mg more preferably approximately 200mg or above.
- the foodstuff can additionally comprise one or more of vitamin A, zinc or one or more fatty acids (such as polyunsaturated fatty acids).
- the polyunsaturated fatty acids may include one or more omega-3 fatty acids (which include eicosapentaenoic acid (EPA), docasahexaenoic acid (DHA) or alpha-linolenic acid (ALA)) or one or more omega-6 fatty acids (which include gamma-linolenic acid (GLA)).
- omega-3 fatty acids which include eicosapentaenoic acid (EPA), docasahexaenoic acid (DHA) or alpha-linolenic acid (ALA)
- omega-6 fatty acids which include gamma-linolenic acid (GLA)
- Each of the fatty acids may be provided in a purified form or by one or more of fish oil, soya oil, blackcurrent oil, sunflower oil or ground nut oil.
- the fatty acids can further be obtained from flaxseed.
- Polyunsaturated fatty acids are anti-inflammatory and anti-oxidant compounds. They are useful in the treatment of atopy, flea allergic dermatitis and pruritus.
- the fatty acids may be provided at levels of approximately lOmg to approximately lOOOmg per 400 kcal preferably from approximately 50mg to approximately 500mg per 400kcal, more preferably approximately 200mg per 400kcal per day or above. Most preferably, eicosapentaenoic acid is provided at a level of approximately 300mg per 400kcal or above and/or docasahexaenoic acid is provided at a level of approximately 200mg per 400kcal or above.
- Zinc is a component of a number of enzyme systems involved in skin and hair growth.
- the role of the zinc may be associated with the adherence of skin scales and hair scales to each other.
- zinc has a role in the immune system.
- Zinc may be provided in the foodstuff of the first aspect at a level (all per 400 kcal) of from approximately 5mg to approximately 50mg, preferably from approximately lOmg to approximately 30mg more preferably approximately 28mg or above.
- the foodstuff further optionally comprises vitamin A or its precursor beta- carotene.
- Vitamin A has strong antioxidant properties and has been shown to be beneficial against selected cancers, cardiovascular diseases, cataracts and age related macular degeneration. Vitamin A is particularly effective at scavenging peroxyl radicals and is a very potent singlet oxygen quencher at low oxygen tensions. Supplementation of the diet with vitamin A has been reported to reduce lipid peroxidation.
- Vitamin A may be provided at a level (all per 400 kcal) of approximately 1000IU to 10,000IU, more preferably 2000IU to 8000IU, most preferably at a level of approximately 5000IU per 400kcal or above.
- a preferred feature of the first aspect provides a foodstuff of the first invention comprising vitamin C, taurine, curcumin and aloe vera and additionally comprising zinc and vitamin A.
- the present invention relates, for all aspects, to any animal.
- the invention relates, in particular, to humans, horses, cats (e.g. Felis domesticus, the domestic cat) and most preferably to dogs (e.g. Canis domesticus, the domestic dog).
- the foodstuff of the invention may be a dry product (with approximately 5 to 12% moisture), a semi -moist product (with approximately 12 to 70% moisture) or a wet product (with approximately 70 to 90% moisture).
- the foodstuff according to the present invention encompasses any product that a animal consumes in its diet.
- the product is a pet food, more particularly a cat or a dog food.
- the invention covers standard food products as well as pet food snacks (for example, snack bars, biscuits and sweet products).
- the foodstuff is preferably a cooked product. It may incorporate meat or animal derived material (such as beef, chicken, turkey, lamb, fish, blood plasma, marrow bone etc or one or more thereof)-
- the product alternatively may be meat free (preferably including a meat substitute such as soya, maize gluten or a soya product) in order to provide a protein source.
- the product may contain additional protein sources such as soya protein concentrate, milk proteins, gluten etc.
- the protein source is a selected protein such as one or more of chicken, rice, catfish, capelin, tapioca or mehaden.
- a selected protein is a protein derived from a minimum number of ingredients, where the ingredients are not commonly associated with sensitivity reactions.
- the product may also contain a starch source such as one or more grains (e.g. corn, rice, oats, barley etc), or may be starch free. It may include a gelatinised starch matrix.
- a starch source such as one or more grains (e.g. corn, rice, oats, barley etc), or may be starch free. It may include a gelatinised starch matrix.
- the foodstuff is preferably packaged. In this way, the consumer is able to identify, from the packaging, the ingredients in the foodstuff and confirm that it is suitable for the particular pet in question.
- the packaging may be metal (usually in the form of a tin or flexifoil), plastic (usually in the form of a pouch or bottle), paper or card. The amount of moisture in any product may influence the type of packaging, which can be used or is required.
- the foodstuff of the invention is preferably a complete and balanced food or is preferably used in combination with a complete and balanced food (for example, as described in National Research Council, 1985, Nutritional Requirements for Dogs, National Academy Press, Washington D.C. or Association of American Feed Control Officials, Official Publication 1996).
- a complete and balanced diet includes a high quality commercial food.
- a high quality commercial food can be defined as a diet manufactured to the nutrient recommendations of the National Research Council, 1985 (supra), wherein the digestibility of key nutrients is 80% or more.
- concentrations of the components to be added to the foodstuff are calculated on the basis of the energy content of the foodstuff and of any additional nutrients which may be consumed by the animal.
- a complete and balanced food (including a high quality commercial food) comprises the foodstuff according to the invention.
- the foodstuff of the first aspect can be provided as a food supplement.
- the food supplement can be a powder, biscuit, kibble, sauce, topping, pocket or tablet that can be administered with or without an additional foodstuff. Where the food supplement is administered with an additional foodstuff, the food supplement can be administered sequentially simultaneously or separately.
- the food supplement may be mixed with the foodstuff, sprinkled or poured over the foodstuff or served separately. Alternatively, the food supplement can be added to a liquid provided for drinking such as water or milk.
- the second aspect of the invention relates to a foodstuff of the first aspect for use in medicine.
- the foodstuff is for use in controlling a skin disorder.
- control and “controlling” mean to decrease or alleviate the symptoms suffered by an animal especially the symptoms of a skin disorder and/or assist in the management of a skin disorder.
- control and “controlling” further mean to promote or aid recovery of the skin for example to improve the appearance and condition of the skin during or after conventional treatment.
- this foodstuff is provided as an adjunct therapy and is preferably provided in combination with a conventional treatment.
- Such conventional treatment may include the administration of a medicament such as a steroid, such as prednisolone and/or hydrocortisone.
- the conventional treatment may further involve the administration of a medicament by any convenient method including orally (including by inhalation), parenteral, mucosal (such as buccal, sublingual, nasal), rectal, transdermal or topical.
- the conventional treatment may involve a topical treatment such as a shampoo, humectant or occlusive.
- Shampoos such as Hibiscrub
- Common ingredients for topical shampoos include coal tar, benzoyl peroxide, selenium sulphide and Ketoconazole.
- Regular use of antimicrobial shampoos may help control secondary pyoderma.
- Topical therapy with humectants and/or occlusives may help to maintain epidermal barrier hydration and inhibit water loss.
- ectoparasites In dogs susceptible to atopy and/or flea allergy, ectoparasites, particularly fleas or scabies, must be rigorously controlled as they will provoke pruritic responses that quickly breach the pruritic threshold.
- Fleas can be treated with products such as Stronghold (Selamectin), Advantage (Imadoclopramid), ProgramTM (Lufenurun), FrontlineTM (Fipronil) or organophosphate derived treatments.
- Scabies may be treated with AludexTM.
- Secondary bacterial infections commonly occur on atopic skin. Such secondary pyoderma is the most common reason for a stable atopic to exhibit increased pruritus. Overt bacterial infection may be treated topically with Hibiscrub, systemically with antibiotic tablets, or with both systemic and topical treatments. Malassezial (for example Malassezia pachydermatis) infections are associated with increased pruritus. Topical antimalassezial shampoos (containing miconazole and/or Ketoconazole) are often useful in controlling secondary malassezial dermatitis.
- Atopy is a common cause of otitis externa and in such cases controlling the underlying atopy may help. Often symptomatic topical therapy is also required. In some cases severe secondary changes, accompanied with thickening of skin causing closure of the ear canal, may require surgery, such as lateral wall resection or vertical canal ablation.
- Symptomatic relief of dogs perennially affected with pruritus can be achieved with immunotherapy. This is obtained by administering a course of injections, usually at monthly intervals, and can take up to six or eight months. During the period of induction it may be necessary to administer low-dose (0.2-0.5mg/kg) glucocorticoids, for example, alternate day prednisolone, prednisone or methylprednisolone (PPMP).
- low-dose 0.2-0.5mg/kg
- glucocorticoids for example, alternate day prednisolone, prednisone or methylprednisolone (PPMP).
- Symptomatic control of pruritus with PPMP, anti-histamines or poly-unsaturated fatty acids may be indicated in, 1) the control of pruritus pending induction of remission with immunotherapy and 2) the control of pruritus in the 60% of dogs that fail to achieve remission with immunotherapy (including also those cases where immunotherapy has not been elected).
- the use of antihistamines to control atopy in dogs is continually being re- evaluated, but failure of one type of antihistamine does not necessarily mean failure of this course of action.
- Typical antihistamines include Clemastine, Chlorpheniramine and hydroxyzine.
- the foodstuff of the invention may allow the reliance on a conventional treatments such as drug or immuno-therapy to be reduced.
- the animal may exhibit less symptoms or the severity of the symptoms may be reduced.
- the animal may exhibit an improved level of well being.
- the skin disorder may be an inflammatory or allergic skin disorder.
- the inflammatory or allergic skin disorder may include one or more of atopy, flea allergic dermatitis, contact allergy, dermatitis, pruritus, alopecia, food sensitivity (especially food sensitivity manifesting as a dermatological disorder) or inflammation.
- the foodstuff of the first aspect is also used for controlling conditions resulting from the skin disorder such as skin irritation, dermatitis and excessive hair loss.
- Disorders such as inflammatory or allergic skin disorders can be complicated by the occurrence of secondary infections caused by bacteria or yeasts.
- the second aspect of the invention further relates to a foodstuff of the invention for use in controlling a bacterial infection associated with a skin disorder in particular in association with an inflammatory or allergic skin disorder.
- the foodstuff of the first aspect assists in the promotion and/or maintenance of skin health.
- the foodstuff will provide the necessary components for rebuilding and maintaining the skin structure.
- the foodstuff of the first aspect can provide benefits to an animal with a skin disorder by reducing itching, reducing the risk of infections and reducing the severity of inflammation, which can be associated with a skin disease or disorder. Furthermore, the foodstuff can enhance and promote the recovery of the skin. In particular, the foodstuff can promote and/or aid recovery from skin diseases such as atopic and/or allergic skin diseases and secondary infections associated therewith. In particular, the foodstuff can aid recovery of skin trauma associated with itching and the resulting damage due to scratching, skin abrasions, inflammation and bacterial infections. The foodstuff may further provide an enhancement and optimisation of skin barrier function.
- the foodstuff of the first aspect may be provided as a commercial product, which will be available from commercial outlets and/or from veterinary surgeons.
- the foodstuff of the first aspect will be provided as required, under the direction of a veterinary surgeon.
- the foodstuff will preferably be fed in combination with one or more specific treatments for a skin disorder under the guidance of a veterinary surgeon.
- the foodstuff will preferably be branded as a dietary aid, or complete foodstuff and preferably not as a medicament. All preferred features of the first aspect of the invention also apply to the second aspect.
- the third aspect of the invention relates to the use of vitamin C, taurine, curcumin and aloe vera in the manufacture of a composition for the control of a skin disorder.
- the third aspect of the invention may further involve the additional use of one or more of zinc, vitamin A or one or more fatty acids in the manufacture of a composition for the prevention or treatment of a skin disorder.
- the composition is a foodstuff.
- the fourth aspect of the invention comprises a method of controlling a skin disorder comprising administering a foodstuff of the first aspect to an animal.
- the animal may be in need thereof.
- the animal is suffering from or has a predisposition to one or more of atopy, FAD, contact dermititis, pruritis, alopecia, inflammatory skin condition and food sensitivity and/or one or more secondary infection associated with one or more of the above conditions.
- the foodstuff is administered daily or twice daily.
- the foodstuff can be administered in combination with or in place of the animal's conventional food.
- the foodstuff is provided as an adjunct therapy and is preferably provided in combination with a conventional therapy.
- the foodstuff can be provided with the conventional therapy to control the skin disorder.
- the foodstuff can be provided after the course of conventional therapy has ended, in order to promote or aid the recovery of the skin by for example, aiding recovery of skin lesions, skin abrasions, skin trauma associated with itching, damage due to scratching, inflammation etc.
- the fifth aspect comprises a process for the preparation of the foodstuff of the first or second aspects.
- the foodstuff can be made according to any method known in the art such as in Waltham Book of Dog and Cat Nutrition, Ed. ATB Edney, Chapter by A. Rainbird, entitled “A Balanced Diet” in pages 57 to 74 Pergamon Press Oxford.
- the components are added together at any time during the processing. They may all be added together at the same time, or individually, in any particular order. Other ingredients of the foodstuff may be added at any time during the processing. Preferably, two or more ingredients of the foodstuff are mixed together and then ground together. The moisture and temperature of the ground particles can be manipulated prior to any further processing step. The components may be added before or after any heating or cooking step.
- the processing may include shaping and/or packaging of the product.
- the product is shaped by extrusion to form pellets or kibbles. Extrusion preferably occurs at a pressure of 20-1000 psig and a temperature of 90-165°C.
- the components of the foodstuff may be mixed with the other components of the foodstuff or can be added to the completed foodstuff.
- one or more of the components for example aloe vera, taurine, curcumin or vitamin C, preferably aloe vera
- one or more components comprising aloe vera, vitamin C, taurine or curcumin are admixed, with one or more other components of the foodstuff.
- the final water content of the foodstuff can be manipulated using a cooler apparatus.
- Figure 1 shows a comparison of plasma vitamin C after incubation of dogs with a control and the foodstuff.
- Figure 2 shows a comparison of plasma taurine after incubation of dogs with a control and the foodstuff.
- Figure 3 shows the effect of the foodstuff and the control on the rate of diffusion of radiolabelled water across an in vitro skin barrier.
- Figure 4 shows the effect of the foodstuff on Keratinocyte skin lipid production.
- Figure 5 shows the positioning of a dish on the for counting of stained cell nuclei.
- Figure 6 shows the effect of the foodstuff on skin recovery.
- Figure 7 shows the effect of the partial foodstuff and the full foodstuff on skin recovery.
- Figure 8 shows the bacteriocidal effect of the foodstuff on the skin isolate SC06.
- Figure 9 shows the bacteriocidal effect of the foodstuff on the skin isolates SCOl, SCO7 and SC08.
- Figure 10 shows the anti-inflammatory effect of the foodstuff on fibroblasts.
- This skin diet provides between approximately 310 and 350 kcal/lOOg.
- the skin diet is a dry diet containing approximately 10% water.
- the skin diet comprises the following ingredients:
- Aloe vera -0.06% Dry raw materials are weighed, mixed and ground. The dry mix is then screened prior to extrusion to form the mixed meal.
- the mixed meal is conveyed to a pre-conditioner where it is mixed with steam, water and oil at specified rates. Sufficient residence time is provided in the pre-conditioner for the moisture and temperature to transfer uniformly throughout the individual particles. The residence time is about two minutes.
- the pre-conditioned mixture is then transferred to an extruder for cooking and forming.
- the die pressure should be 200 - 1000 psig and the die temperature is about 90 - 165 °C.
- the formed kibble is pneumatically conveyed to the dryer.
- the drying temperature is set at 130 - 145 °C and drying time is about 17 minutes.
- the product moisture exiting the dryer should be less than 12%.
- the dried kibble is sized (or screened) before coating to reduce clumps and fines.
- the kibble is fed into a coating system where coating is applied uniformly across the surface of the kibble at a constant application rate.
- the coating materials include digest and a mixture of Aloe Vera Extract powder and oil.
- the Aloe powder/ oil mixture is prepared by dispersing an accurate amount of Aloe Vera Extract powder into a fixed amount of oil. The mixture must be well mixed, i.e., all Aloe powder is uniformly dispersed in the oil, prior to application.
- the kibble is coated with the Aloe powder/ oil mixture first followed by digest at ambient temperature.
- the coated kibble is then transferred to a post-coat cooler in which the coated product is conditioned to its final moisture ( ⁇ 12%), water activity ( ⁇ 0.7 at 35 °C) and temperature ( ⁇ 35 °C) prior to packaging.
- the retention time is about 15 minutes.
- a panel of dogs underwent a feeding trial to compare the effects of feeding the foodstuff with a control diet.
- the control diet contained the same ingredients as the foodstuff minus vitamin C, curcumin, taurine and aloe vera.
- the dogs fed with the foodstuff showed a benefit compared to those on the control diet. Further, no deleterious side effects were observed with the foodstuff.
- control diet Both the control diet and the curcumin enriched diet provided 405kCal 100g.
- the control diet was a dry diet containing approximately 4% water.
- the control diet comprised the following ingredients:
- the curcumin-supplemented diet comprised 0.5% by weight curcumin.
- the curcumin was sprayed onto the external surface of the dry control product. Measurement of Immunoglobulin Levels
- Serum NO was determined by the Griess reaction. Griess reaction tests were obtained from Promega and performed as described in the provided protocol sheets. In brief, 50 ⁇ l of serum sample and NO standard (diluted in FCS) was added in duplicate to wells in a 96 well plate. 50 ⁇ l of Sulphanilamide solution was dispensed to each well and the plate incubated in the dark at RT° for 5-10 minutes. After incubation 50 ⁇ l of NED solution was added to each well and again incubated in the dark for 5- 10 minutes at RT°. The optical density of each well was determined immediately using a microplate reader set between 520 and 550nm. Serum nitric oxide concentration (uM) was calculated from a standard curve. Immunoglobulin levels in the serum of the cats
- test group were fed for 9 weeks on a control diet with curcumin (500mg/400kcal), aloe vera (70 mg/400kcal) Vitamin C (350 mg/400kcal) and Taurine (500 mg/400kcal) added on top of the diet.
- curcumin 500mg/400kcal
- aloe vera 70 mg/400kcal
- Vitamin C 350 mg/400kcal
- Taurine 500 mg/400kcal
- PGE Prostaglandin
- Ig Immunoglobulin
- APP Acute Phase Protein
- WBC White Blood Cell
- FACS Fluorescent Activated Cell Sorting
- E- Toxin Endo-Toxin
- Lip Perox lipid peroxidation (plasma)
- LK Leukotriene
- EDTA Ethylenediaminetetra acetic acid
- RID Radial immunodiffusion.
- This assay demonstrates the effect of the foodstuff comprising Vitamin C, Taurine, Aloe Vera and Curcumin, on improving barrier function, as assessed by use of the diffusion assay.
- the rate of diffusion of radiolabelled water across an in vitro skin barrier was compared in cells cultured both in the presence and absence of the foodstuff.
- Costar Snapwell plates (ASL Cat No. 402/0369/08) were set up containing 2.6ml Greens media in the outer well and 400 ⁇ l Greens in the inner well, the latter was seeded with canine keratinocytes at 1 x 10 5 . These plates were incubated at 37°C, 5% C0 2 . The Greens media in the inner well was changed the following day to remove any dead cells. These plates were cultured for a further two days. Greens media was prepared containing test concentrations of foodstuff (lO ⁇ l/ml). Control media was also prepared containing DMSO (lO ⁇ l ml). On day four the media was removed from the inner and outer wells and 900 ⁇ l of test/control media was replaced into the outer well.
- Canine keratinocytes were seeded in MCDB 153 media (see contents below) into collagen coated 24 well plates (Sigma, Cat No.Z38,049-0) at a cell density ' of 5 x 10 4 per well. These plates were incubated at 37°C, 5% C0 2 . The following day the media was changed on each well to remove any dead cells. On day four of incubation the media was changed again (500 ⁇ l of MCDB 153 without BPE). Foodstuff was then added at varying test concentrations (lO ⁇ l/ml), DMSO was added to the control wells (lO ⁇ l/ml), six wells were used per test/control.
- the level of ceramide synthesis in the skin is increased in cells, which have been cultured in the presence of the foodstuff. This data suggests that incubation of the cells in the presence of the foodstuff could improve barrier function through increasing the level of lamellar lipid synthesis and thus helps to create skin with improved barrier function. In turn this will prevent the perfusion of pathogens or allergens through the skin which could lead to infection or allergy, respectively.
- This assay determine the effect of the foodstuff (Vitamin C, Taurine, Aloe Vera, Curcumin) on improving skin recovery in an in vitro wound scenario as investigated by use of skin recovery assay.
- the ability of canine dermal fibroblast cells to migrate, post- wounding, was compared in cells cultured both in the presence and absence of the foodstuff.
- tissue culture dishes (with lid and vent, sterile, 35mm x 10mm, 2 x 2mm grid, 174926Nalge Nunc international) were used with a line drawn on the underside of each dish approximately down the centre line to represent the wound line.
- Two dishes were allocated as control and two for the test experiments.
- the dishes were then seeded with canine dermal fibroblasts (approximately 4 x 10 5 per dish in 2 ml of fibroblast media) and incubated overnight at 37 C.
- tissue culture dishes were checked for confluency using a phase contrast microscope.
- Media was removed from the plate (1 ml) to aid in scraping and each plate was scraped of cells from the wound line over half the plate using a Cell Scraper (Nunc 179693, 23cm). To insure that half the cells had been removed from the plate they were viewed again under the phase contrast microscope. The remaining media was removed and the cells were then washed with 1ml of fibroblast media. A further 2mls of Fibroblast media + 20 ⁇ l of DMSO (control) or Test substance (foodstuff) was added and the cells were incubated at 37°C for 48 hours.
- DMSO control
- Test substance foodstuff
- each dish was positioned on the phase contrast microscope with the 'wound' to the right -hand side.
- the skin recovery assay was then carried out as discussed above in order to compare the effect of the foodstuff (Vitamin C, Taurine, Aloe Vera, Curcumin) on a control foodstuff and on a partial foodstuff (Vitamin C and Taurine).
- the canine dermal fibroblasts were cultured on plastic and then half of the confluent monolayer was removed with a cell scraper. Both partial and full foodstuff were present at 0.125mg/ml.
- SC01 Exiguobacterium species - formerly known as Corynebacterium species and belong to the family of Coryneform bacteria. The species associated with infections are E. acetyliticum and E. auranticicum. A number of clinically reported strains have been isolated from various sources e.g. Skin, wounds and cerebrospinal fluid. They are motile by peritrichous flagella, facultatively anaerobic with fermentative carbohydrate metabolism.
- SC02 Staphylococcus intermedius - They are normal inhabitants of the skin and hair surface, and mucous membranes. However Staphylococcus intermedius is the most frequently isolate from the lesions of canine pyoderma. They are gram positive cocci, facultative anaerobes and are increasingly becoming associated (as opportunistic pathogens) with serious infections. It also has growing prevalence of resistance to many antibiotics.
- SC03 Bacillus licheniformis - It is a Gram-positive, motile, spore-forming facultatively anaerobic rod. Food poisoning caused by Bacillus licheniformis is characterised by diarrhoea, although vomiting occurs in half of reported cases. The food poisoning has been associated with cooked meat, poultry and vegetable dishes (particularly meals served with rice).
- SC04 Bacillus pumilus - It is a gram-positive, motile, facultatively anaerobic rod. Food poisoning caused by Bacillus pumilus is characterised by vomiting and diarrhoea. The food poisoning has been associated with meat pie's, eggs, cheese and fruit juice.
- Bacillus pumilus and its metabolites have been suggested to have antibacterial properties and have the potential as a biocontrol agent of moulds and mycotoxins in cereal grains and food commodities.
- SC05 Macrococcus caseolyticus - It is a gram-positive, coccoid, non-motile, not capsulated, facultative anaerobe but with a strong preference towards aerobic conditions.
- the optimum growth temperature is 35°c. It has a positive reaction for catalyse and oxidase.
- Neisseria canis Nearly all species of Neisseria are aerobic gram- negative diplococci. They are cytochrome oxidase and catalase positive and non- fastidious. They have optimal growth in a moist atmosphere.
- the natural habitat of Neisseria species is the mucous membranes of the respiratory tracts of warm-blooded animals. Neisseria canis has been isolated from the throats of dogs and cats and has been reported to cause infection in cat and dog bite wounds of humans.
- SC07 Psychrobacter phenylpyruvicus - Psychrobacter- a proposed genus to be included in the family Neisseriaceae. They are short gram-negative rods, most often occurring as diplobacilli. They are nonmotile, non-endospores. The optimal temperature for growth is 33 to 37°c. Strains are aerobic, catalase and oxidase positive. Strains have been isolated from genitourinary tract, blood, cerebrospinal fluid and pus of various lesions. Species associated with infection, P. immobilis and P. phenylpyruvicus. Associated infections, meningitis, bacteraemia and eye infections.
- SCQ8 Macrococcus caseolyticus - Same as SC05
- E. coli - E.coli is a gram-negative, aerobe.
- Optimal growth temperature is 37°. It is one of the most common inhabitants of the intestinal tract and skin flora. Generally most species are not considered pathogenic, however can cause disease under certain conditions. Pathogenic strains can cause food poisoning associated with diarrhoea or other serious infections.
- Propionibacterium acnes are widely distributed on human skin, hair, oropharynx, gastrointestinal tract and is considered to cause skin disorders and acne. It is a gram-positive, non-spore forming anaerobic rod. The organism is found on the oily areas of the skin such as the scalp and forehead. It is thought that P. acnes is a member of the normal canine microflora which can be transferred to man. The distribution of the organism was found to be similar to that found on man, however the organism appears to be well adapted to the dog and in not thought to be associated with any canine dermatoses (Muller et al 1989).
- the foodstuff is made up of the following ingredients Vitamin C, Taurine, Aloe vera and Curcumin as outlined below, in 50ml BHI broth at lmg of foodstuff/lml BHI broth. This is then vigorously votexed and then incubated 38°c.
- Both tubes (control) and (test) for each strain should contain a final volume of 10ml. Tubes are then incubated at 38°c.
- Vitamin C 30mg /400kcal
- the foodstuff was tested at concentrations ranging from 0.1mg/ml-20mg/ml. These concentrations correspond to the amount of foodstuff available in the blood after feeding 300g of the diet per day to an average size dog.
- the foodstuff is dissolved in DMSO in order to solubilise the ingredients when incubating the foodstuff with the bacterial.
- Staph I A small effect in decreasing the growth is observed at 6 hours but not at 24 hours. At 24 hours a slight increase in growth is observed. This indicates that the foodstuff is having a bacteriostatic on Staph I
- SC06 There is a massive effect of decreasing the growth of SC06 overtime and with different concentrations of the foodstuff. This indicates that the foodstuff is showing bacteriostatic properties, and at 24hours in some concentrations is it actually showing bactericidal properties, (results as indicated in figure 8) SCOl, SC03, SC04, SC05, SC07, SC08 show an average decrease in growth in the presence of the cocktail.
- Figure 9 indicates data for SC08, 7 and 1 after 6 hours and 24 hours in culture. The experiments were run in triplicate and using the same methods as described above. The graphs demonstrate an inhibitory effect of all three isolates and indicates that the skin support cocktail will be beneficial in controlling secondary infections.
- a dachshund (6 years old, female) has suffered from a skin condition for 4 years.
- a number of treatments were used in the past to alleviate this condition including steroid, anti-histamine, fatty-acids, antibiotics, psychotrophic, elimination diet, shampoo and ear care.
- Various diets had also been used including fish, meat, chicken and vegetable diets.
- the dog was fed on the skin diet for 3 months following a 3 month period on a control diet. During the time the dog was fed on the skin diet, the owner noticed a number of improvements in the condition of the dogs skin including an overall improvement in skin condition, the disappearance of a reddish skin area on the dogs foot and an improvement in a skin lesion on the dogs back. The owner wishes to continue feeding the skin diet to the dog after the trial has ended.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002592742A JP4199009B2 (en) | 2001-06-01 | 2002-05-31 | Skin meal |
| DE60228235T DE60228235D1 (en) | 2001-06-01 | 2002-05-31 | ANIMAL NUTRITIONAL COMPOSITION FOR IMPROVING THE SKIN |
| EP02738346A EP1392131B1 (en) | 2001-06-01 | 2002-05-31 | Skin diet for pets |
| DK02738346T DK1392131T3 (en) | 2001-06-01 | 2002-05-31 | Skin Diet Feeds for Pets |
| US10/479,065 US8647681B2 (en) | 2001-06-01 | 2002-05-31 | Skin diet |
| CA2449146A CA2449146C (en) | 2001-06-01 | 2002-05-31 | Skin diet |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0113348.7A GB0113348D0 (en) | 2001-06-01 | 2001-06-01 | Skin diet |
| GB0113348.7 | 2001-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002096221A2 true WO2002096221A2 (en) | 2002-12-05 |
| WO2002096221A3 WO2002096221A3 (en) | 2003-01-16 |
Family
ID=9915721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2002/002538 Ceased WO2002096221A2 (en) | 2001-06-01 | 2002-05-31 | Skin diet |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8647681B2 (en) |
| EP (1) | EP1392131B1 (en) |
| JP (1) | JP4199009B2 (en) |
| AT (1) | ATE404075T1 (en) |
| AU (1) | AU785003B2 (en) |
| CA (1) | CA2449146C (en) |
| DE (1) | DE60228235D1 (en) |
| DK (1) | DK1392131T3 (en) |
| ES (1) | ES2312583T3 (en) |
| GB (2) | GB0113348D0 (en) |
| WO (1) | WO2002096221A2 (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003113079A (en) * | 2001-09-28 | 2003-04-18 | Kao Corp | Pyoderma treatment |
| FR2841128A1 (en) * | 2002-06-21 | 2003-12-26 | Oreal | Oral administration of taurine and hypotaurine for the prevention and treatment of hair loss |
| WO2004000293A3 (en) * | 2002-06-21 | 2004-05-13 | Oreal | Use of taurine or derivatives thereof for the treatment of alopecia |
| EP1414386A4 (en) * | 2001-08-10 | 2005-02-23 | Mars Inc | Canine cardiac diet |
| ITSA20090007A1 (en) * | 2009-03-18 | 2009-06-17 | Aristide Maffei | ALOE JUICE ADDITIONAL SURFACE PROCESS ON VEGETABLE FOODS R ANIMALS |
| WO2012143576A3 (en) * | 2012-08-23 | 2013-05-02 | Symrise Ag | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) |
| EP2532250A4 (en) * | 2010-02-03 | 2013-08-21 | Morinaga Milk Industry Co Ltd | PROCESS FOR PRODUCING ALOE POWDER |
| US8647681B2 (en) | 2001-06-01 | 2014-02-11 | Mars, Inc. | Skin diet |
| US8968806B2 (en) * | 2005-04-26 | 2015-03-03 | Sean Joseph Delaney | Method and system for creating and using a supplement to balance animal diets |
| US10052299B2 (en) | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| US10058522B2 (en) | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Oxidative retinal diseases |
| US10058612B2 (en) | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| US10154978B2 (en) | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Disorders implicating PUFA oxidation |
| US10154983B2 (en) | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| KR20190086421A (en) * | 2019-07-11 | 2019-07-22 | 주식회사 미싹바이오 | Companion animal nutrient containing collagen extract and method for producing the same |
| EP2377875B1 (en) * | 2008-11-19 | 2020-09-02 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| US11298306B2 (en) | 2017-12-12 | 2022-04-12 | Colgate-Palmolive Company | Personal care composition |
| US11400032B2 (en) | 2013-12-20 | 2022-08-02 | Colgate-Palmolive Company | Tooth whitening oral care product with core shell silica particles |
| US11447441B2 (en) | 2015-11-23 | 2022-09-20 | Retrotope, Inc. | Site-specific isotopic labeling of 1,4-diene systems |
| US11602495B2 (en) | 2013-12-20 | 2023-03-14 | Colgate-Palmolive Company | Core shell silica particles and use for malodor reduction |
| US11779910B2 (en) | 2020-02-21 | 2023-10-10 | Biojiva Llc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006018178A1 (en) * | 2006-04-18 | 2007-10-31 | Schröder, Jan | Animal feed obtained from Aloe vera as gel, concentrate, essence and/or as original source material for the following animals e.g. cats, dogs, rabbits, mice, sea pigs, snakes, reptiles, spiders, rats, insects camels, alpacas and horses |
| DE102007009554A1 (en) * | 2007-02-27 | 2008-08-28 | Berer, Erich, Dr. | Crispy nibbling article comprises a core made of crispy material covered with a layer, which contains a stimulation agent, vitamin, flavor material, an acidifying agent and a metal carbonate in a concentration |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| JP6238406B2 (en) * | 2011-06-03 | 2017-11-29 | 大正製薬株式会社 | Composition for maintaining or improving skin barrier function |
| JP5930507B2 (en) * | 2011-06-03 | 2016-06-08 | 大正製薬株式会社 | Hyaluronic acid production promoter |
| AU2012287067B2 (en) | 2011-07-25 | 2016-12-08 | Dermaforce Holdings, LLC | Botanical antioxidant compositions and methods of preparation and use thereof |
| DE102011052687A1 (en) | 2011-08-12 | 2013-02-14 | Lohmann Animal Health Gmbh | Use of antioxidants |
| JP6168485B2 (en) * | 2015-11-27 | 2017-07-26 | 大正製薬株式会社 | Hyaluronic acid production promoter |
| AU2016406769B2 (en) * | 2016-05-10 | 2019-02-07 | Colgate-Palmolive Company | Taurine and aloe synergistic anti-irritant compositions and methods |
| TWI874418B (en) * | 2019-07-02 | 2025-03-01 | 美商瑪斯公司 | Animal food composition |
| CN115363205A (en) * | 2022-08-08 | 2022-11-22 | 完美(广东)日用品有限公司 | Composition with immunity enhancing and anti-inflammatory functions and preparation method thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468737A (en) * | 1982-05-07 | 1995-11-21 | Carrington Laboratories, Inc. | Wound healing accelerated by systemic administration of polysaccharide from aloe |
| GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
| JPS6034156A (en) * | 1983-08-08 | 1985-02-21 | Hayashibara Biochem Lab Inc | Eicosapentaenoic acid clathrate compound and food and drink containing the same |
| US4602004A (en) * | 1984-06-14 | 1986-07-22 | Maurice Cohen | Aloin and aloe-emodin containing pesticides |
| US4629625A (en) * | 1984-08-29 | 1986-12-16 | Gaull Gerald E | Human nutritional compositions containing taurine and vitamins and/or minerals |
| US4725438A (en) * | 1986-05-29 | 1988-02-16 | Leazer Billie S | Aloe vera ointment |
| US4704280A (en) * | 1986-12-19 | 1987-11-03 | Bates Harry L | Cosmetic lotion |
| JP2568833B2 (en) | 1987-02-27 | 1997-01-08 | 大洋香料株式会社 | Caries prevention agent |
| US5244921A (en) * | 1990-03-21 | 1993-09-14 | Martek Corporation | Eicosapentaenoic acids and methods for their production |
| DE4100975A1 (en) | 1991-01-15 | 1992-07-16 | Weuffen Wolfgang | Cosmetic or pharmaceutical preparations for improving hair quality and promoting hair growth |
| DE4316293C2 (en) | 1993-05-14 | 1996-05-09 | Jobst Krauskopf | Use of a combination of anserine / carnosine and hypotaurine / taurine to combat inflammatory diseases |
| US5449517A (en) * | 1993-11-22 | 1995-09-12 | Fitzjarrell; Edwin A. | Method and formulation for eliminating fleas on animals |
| IL112205A0 (en) | 1994-01-06 | 1995-03-15 | Res Dev Foundation | Curcumin, analogues of curcumin and novel uses thereof |
| JPH07277939A (en) | 1994-04-05 | 1995-10-24 | Dowa Mining Co Ltd | Skin external preparation |
| CA2147109A1 (en) | 1994-04-18 | 1995-10-19 | Gregory A. Reinhart | Pet food product containing omega-6 and omega-3 fatty acids and process for reducing inflammatory skin responses |
| EP0704210B1 (en) * | 1994-09-30 | 2002-12-04 | L'oreal | Use of an agonist of a receptor associated to a chloride channel in the treatment of wrinkles |
| US5643623A (en) * | 1995-06-07 | 1997-07-01 | Mars Incorporated | Health food product and its uses |
| JPH0930987A (en) | 1995-07-20 | 1997-02-04 | Mikio Ito | Preparation for treatment or prevention of refractory ulcer, gastritis and dermatitis |
| JPH09143063A (en) * | 1995-11-22 | 1997-06-03 | Kose Corp | Composition suitable for external use |
| US6168802B1 (en) * | 1996-05-31 | 2001-01-02 | The Howard Foundation | Compositions containing creatine and aloe vera extract |
| US5824659A (en) | 1996-09-04 | 1998-10-20 | Board Of Regents, The University Of Texas System | Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation |
| US5989604A (en) * | 1996-12-19 | 1999-11-23 | Adore-A-Pet, Ltd. | Xylitol-containing non-human foodstuff and method |
| US5925357A (en) * | 1997-03-14 | 1999-07-20 | Carrington Laboratories, Inc. | Bifurcated method to process aloe whole leaf |
| US6127409A (en) * | 1997-04-30 | 2000-10-03 | Showa Denko Kabushiki Kaisha | Ascorbic acid derivative and vitamin C preparation containing the same |
| JPH10298174A (en) | 1997-04-30 | 1998-11-10 | Showa Denko Kk | Ascorbic acid derivative and vitamin c agent containing the same |
| AU5416998A (en) * | 1997-10-14 | 1999-05-03 | Quest International B.V. | Preparation for the enhancement of the antioxidant status of cells |
| US6007861A (en) * | 1997-10-17 | 1999-12-28 | Von Lempke; Frederick Ernst | Process for the preparation and the packaging of soya based foodstuff |
| US6107334A (en) * | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
| US6117477A (en) * | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
| US6149932A (en) | 1998-03-24 | 2000-11-21 | Stabar Enterprises, Inc. | Dietary supplement for preventing or reducing shedding of hair |
| US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
| US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
| JP2000083620A (en) * | 1998-09-04 | 2000-03-28 | Tomoji Tanaka | Healthy food and healthy drink mixed with additive for rapidly degrading alcohol |
| DE19910697C2 (en) * | 1999-03-10 | 2003-06-05 | Beate Ploch | Process for the preparation of a therapeutically active substance and use thereof |
| JP2000290189A (en) * | 1999-04-09 | 2000-10-17 | Janifu Tekku:Kk | Antiallergic agent |
| CN1095377C (en) * | 1999-04-29 | 2002-12-04 | 湖北三峡学院 | Medicine for treating skin ringworm and dermatitis and preparation process |
| CN1272340A (en) * | 1999-04-29 | 2000-11-08 | 长春市芦荟应用研究所 | Aloe life egg soluble powder preparation |
| CN1272324A (en) * | 1999-04-29 | 2000-11-08 | 长春市芦荟应用研究所 | Aloe chewing sweets |
| US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
| US20010051184A1 (en) * | 1999-05-20 | 2001-12-13 | Madalene C.Y. Heng | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases |
| US6673843B2 (en) * | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
| AU7880700A (en) * | 1999-08-16 | 2001-03-13 | Dung Phan | Compositions and methods of treatment for skin conditions using extracts of turmeric |
| US6737089B2 (en) * | 1999-08-27 | 2004-05-18 | Morinda, Inc. | Morinda citrifolia (Noni) enhanced animal food product |
| AU783688B2 (en) | 1999-09-06 | 2005-11-24 | Good Health Products Limited | Improvements in or relating to consumable health products |
| US6333063B2 (en) * | 1999-12-28 | 2001-12-25 | Kikkoman Corporation | High-protein food of plate form |
| US6630158B2 (en) * | 2000-10-31 | 2003-10-07 | Stiefel Laboratories, Inc. | Dietary supplement composition and method for improving and maintaining healthy skin |
| GB0113348D0 (en) | 2001-06-01 | 2001-07-25 | Mars Uk Ltd | Skin diet |
-
2001
- 2001-06-01 GB GBGB0113348.7A patent/GB0113348D0/en not_active Ceased
-
2002
- 2002-03-27 AU AU29174/02A patent/AU785003B2/en not_active Expired
- 2002-05-31 CA CA2449146A patent/CA2449146C/en not_active Expired - Lifetime
- 2002-05-31 EP EP02738346A patent/EP1392131B1/en not_active Expired - Lifetime
- 2002-05-31 WO PCT/GB2002/002538 patent/WO2002096221A2/en not_active Ceased
- 2002-05-31 US US10/479,065 patent/US8647681B2/en not_active Expired - Fee Related
- 2002-05-31 DE DE60228235T patent/DE60228235D1/en not_active Expired - Lifetime
- 2002-05-31 ES ES02738346T patent/ES2312583T3/en not_active Expired - Lifetime
- 2002-05-31 AT AT02738346T patent/ATE404075T1/en not_active IP Right Cessation
- 2002-05-31 JP JP2002592742A patent/JP4199009B2/en not_active Expired - Lifetime
- 2002-05-31 DK DK02738346T patent/DK1392131T3/en active
- 2002-05-31 GB GB0212767A patent/GB2378133B/en not_active Expired - Lifetime
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647681B2 (en) | 2001-06-01 | 2014-02-11 | Mars, Inc. | Skin diet |
| EP1414386A4 (en) * | 2001-08-10 | 2005-02-23 | Mars Inc | Canine cardiac diet |
| JP2003113079A (en) * | 2001-09-28 | 2003-04-18 | Kao Corp | Pyoderma treatment |
| US9138408B2 (en) | 2002-06-21 | 2015-09-22 | L'oreal | Use of taurine for treating alopecia |
| FR2841128A1 (en) * | 2002-06-21 | 2003-12-26 | Oreal | Oral administration of taurine and hypotaurine for the prevention and treatment of hair loss |
| WO2004000293A3 (en) * | 2002-06-21 | 2004-05-13 | Oreal | Use of taurine or derivatives thereof for the treatment of alopecia |
| US8968806B2 (en) * | 2005-04-26 | 2015-03-03 | Sean Joseph Delaney | Method and system for creating and using a supplement to balance animal diets |
| EP2377875B1 (en) * | 2008-11-19 | 2020-09-02 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| ITSA20090007A1 (en) * | 2009-03-18 | 2009-06-17 | Aristide Maffei | ALOE JUICE ADDITIONAL SURFACE PROCESS ON VEGETABLE FOODS R ANIMALS |
| USRE49238E1 (en) | 2009-10-30 | 2022-10-11 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| US10052299B2 (en) | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| US11510888B2 (en) | 2009-10-30 | 2022-11-29 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
| EP2532250A4 (en) * | 2010-02-03 | 2013-08-21 | Morinaga Milk Industry Co Ltd | PROCESS FOR PRODUCING ALOE POWDER |
| US11241409B2 (en) | 2011-04-26 | 2022-02-08 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| US12156860B2 (en) | 2011-04-26 | 2024-12-03 | Biojiva Llc | Disorders implicating PUFA oxidation |
| US10058522B2 (en) | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Oxidative retinal diseases |
| US10058612B2 (en) | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| US10154978B2 (en) | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Disorders implicating PUFA oxidation |
| US10154983B2 (en) | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| US11285125B2 (en) | 2011-04-26 | 2022-03-29 | Retrotope, Inc. | Oxidative retinal diseases |
| WO2012143576A3 (en) * | 2012-08-23 | 2013-05-02 | Symrise Ag | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) |
| US11951196B2 (en) | 2013-12-20 | 2024-04-09 | Colgate-Palmolive Company | Core shell silica particles and use for malodor reduction |
| US11400032B2 (en) | 2013-12-20 | 2022-08-02 | Colgate-Palmolive Company | Tooth whitening oral care product with core shell silica particles |
| US12324848B2 (en) | 2013-12-20 | 2025-06-10 | Colgate-Palmolive Company | Core shell silica particles and uses thereof as an anti-bacterial agent |
| US11602495B2 (en) | 2013-12-20 | 2023-03-14 | Colgate-Palmolive Company | Core shell silica particles and use for malodor reduction |
| US12350354B2 (en) | 2013-12-20 | 2025-07-08 | Colgate-Palmolive Company | Core shell silica particles and use for malodor reduction |
| US11447441B2 (en) | 2015-11-23 | 2022-09-20 | Retrotope, Inc. | Site-specific isotopic labeling of 1,4-diene systems |
| US11453637B2 (en) | 2015-11-23 | 2022-09-27 | Retrotope, Inc. | Site-specific isotopic labeling of 1,4-diene systems |
| US12060324B2 (en) | 2015-11-23 | 2024-08-13 | Biojiva Llc | Site-specific isotopic labeling of 1,4-diene systems |
| US11779529B2 (en) | 2017-12-12 | 2023-10-10 | Colgate-Palmolive Company | Personal care composition |
| US11298306B2 (en) | 2017-12-12 | 2022-04-12 | Colgate-Palmolive Company | Personal care composition |
| KR102113422B1 (en) | 2019-07-11 | 2020-05-20 | 주식회사 미싹바이오 | Pet food supplement containing collagen extract and its manufacturing method |
| KR20190086421A (en) * | 2019-07-11 | 2019-07-22 | 주식회사 미싹바이오 | Companion animal nutrient containing collagen extract and method for producing the same |
| US11779910B2 (en) | 2020-02-21 | 2023-10-10 | Biojiva Llc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2449146A1 (en) | 2002-12-05 |
| JP4199009B2 (en) | 2008-12-17 |
| GB2378133B (en) | 2005-01-26 |
| EP1392131A2 (en) | 2004-03-03 |
| ATE404075T1 (en) | 2008-08-15 |
| GB2378133A (en) | 2003-02-05 |
| JP2004520848A (en) | 2004-07-15 |
| US8647681B2 (en) | 2014-02-11 |
| EP1392131B1 (en) | 2008-08-13 |
| GB0212767D0 (en) | 2002-07-10 |
| ES2312583T3 (en) | 2009-03-01 |
| WO2002096221A3 (en) | 2003-01-16 |
| US20040241286A1 (en) | 2004-12-02 |
| DE60228235D1 (en) | 2008-09-25 |
| AU785003B2 (en) | 2006-08-24 |
| GB0113348D0 (en) | 2001-07-25 |
| DK1392131T3 (en) | 2008-11-17 |
| AU2917402A (en) | 2002-12-05 |
| CA2449146C (en) | 2012-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2449146C (en) | Skin diet | |
| AU2011201203B2 (en) | Methods for promoting health or wellness in adult animals | |
| AU2011100404A4 (en) | Methods for enhancing palatability of compositions for animal consumption | |
| JP2019528698A (en) | Compositions and methods for modulating gastrointestinal microbiota in canines | |
| EP1637041B1 (en) | Improving longevity of elderly cats | |
| US20230058302A1 (en) | Products and methods for inhibiting respiratory conditions | |
| AU2009316370B2 (en) | Methods for altering food intake, modifying nutrient digestibility and altering stool quality and/or stool frequency | |
| JP2025081609A (en) | Pet food composition | |
| AU2004212250B2 (en) | Skin composition | |
| WO2023154792A1 (en) | Pet food compositions | |
| Belghiti et al. | Promoting of Growth in Ross 208 Chicken Broilers Following a Diet Based on Opuntia ficus-Indica (Prickly Pear) Fruit | |
| WO2023230030A1 (en) | Pet food compositions | |
| EP4704595A1 (en) | Pet food compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2449146 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002592742 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002738346 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002738346 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10479065 Country of ref document: US |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2002738346 Country of ref document: EP |






